Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 16.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp |
| 12.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | mendment is to amend and restate in its entirety, Item 5.02 of the Original Form 8-K to disclose the future grant date o |
Stammdaten
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Unternehmen & Branche
| Name | LadRx Corp |
|---|---|
| Ticker | LADX |
| CIK | 0000799698 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 232828509 |
|---|---|
| ISIN | US2328285091 |
| Typ | Common Stock |
| Marktkapitalisierung | 51.985 USD |
| Beta | 0,80 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-03-31 | 10-Q | -719,291 | -1.45 | 260,073 | -2,134,792 | |
| 2024-12-31 | 10-K | -1,589,685 | -3.21 | 839,512 | -1,419,429 | |
| 2024-09-30 | 10-Q | -824,540 | -1.67 | 74,374 | -1,754,464 | |
| 2024-06-30 | 10-Q | -1,282,987 | -2.59 | 893,909 | -933,851 | |
| 2024-03-31 | 10-Q | 186,735 | 0.38 | 2,221,274 | 345,208 | |
| 2023-12-31 | 10-Q | -3,800,000 | 2,307,882 | 107,354 | ||
| 2023-12-31 | 10-K | 400,443 | 0.68 | 2,307,882 | 107,354 | |
| 2023-09-30 | 10-Q | -815,989 | -1.65 | 3,065,566 | 965,390 | |
| 2023-06-30 | 10-Q | 3,148,966 | 6.45 | 3,982,285 | 1,781,379 | |
| 2023-03-31 | 10-Q | -1,074,498 | -0.03 | 1,230,438 | -1,806,117 | |
| 2022-12-31 | 10-K | -4,200,573 | -0.11 | 2,246,772 | -1,317,964 | |
| 2022-09-30 | 10-Q | -1,166,679 | -2.78 | 3,379,139 | -307,260 | |
| 2022-06-30 | 10-Q | -793,776 | -2.25 | 5,031,534 | 940,588 | |
| 2022-03-31 | 10-Q | -1,295,911 | 6,564,321 | 1,266,458 | ||
| 2021-12-31 | 10-K | -13,176,663 | 8,726,777 | 753,719 | ||
| 2021-09-30 | 10-Q | -1,695,253 | 17,037,031 | 9,951,698 | ||
| 2021-06-30 | 10-Q | -1,175,796 | 9,300,811 | 6,493,861 | ||
| 2021-03-31 | 10-Q | -1,279,303 | 10,621,560 | 7,591,657 | ||
| 2020-12-31 | 10-K | -6,700,606 | 12,060,227 | 8,870,960 | ||
| 2020-09-30 | 10-Q | -2,774,558 | 15,369,480 | 10,215,478 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 30.06.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. | 1 | 1 | 100.00 |